Los Angeles Capital Management LLC Buys New Position in Repligen Co. (NASDAQ:RGEN)

Los Angeles Capital Management LLC purchased a new position in Repligen Co. (NASDAQ:RGEN) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 5,368 shares of the biotechnology company’s stock, valued at approximately $965,000.

A number of other large investors also recently modified their holdings of RGEN. Natixis Advisors L.P. grew its stake in shares of Repligen by 27.4% in the fourth quarter. Natixis Advisors L.P. now owns 36,727 shares of the biotechnology company’s stock worth $6,603,000 after acquiring an additional 7,892 shares during the last quarter. New York Life Investment Management LLC grew its position in Repligen by 6.8% in the 4th quarter. New York Life Investment Management LLC now owns 5,904 shares of the biotechnology company’s stock worth $1,062,000 after purchasing an additional 375 shares during the last quarter. Victory Capital Management Inc. increased its holdings in shares of Repligen by 9.5% during the 4th quarter. Victory Capital Management Inc. now owns 21,271 shares of the biotechnology company’s stock worth $3,825,000 after purchasing an additional 1,851 shares during the period. Norden Group LLC raised its position in shares of Repligen by 53.8% during the fourth quarter. Norden Group LLC now owns 2,142 shares of the biotechnology company’s stock valued at $385,000 after buying an additional 749 shares during the last quarter. Finally, Retirement Systems of Alabama lifted its stake in shares of Repligen by 0.4% in the fourth quarter. Retirement Systems of Alabama now owns 65,032 shares of the biotechnology company’s stock valued at $11,693,000 after buying an additional 288 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RGEN has been the topic of several research reports. JPMorgan Chase & Co. lowered their price target on Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. Stifel Nicolaus upped their target price on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. Finally, KeyCorp raised their target price on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $197.75.

Insider Transactions at Repligen

In related news, CEO Anthony Hunt sold 16,707 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the sale, the chief executive officer now directly owns 185,249 shares in the company, valued at approximately $36,575,562.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Anthony Hunt sold 16,707 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the transaction, the chief executive officer now owns 185,249 shares in the company, valued at approximately $36,575,562.56. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Karen A. Dawes sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the sale, the director now owns 87,367 shares of the company’s stock, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,597 shares of company stock valued at $5,039,532. Corporate insiders own 1.20% of the company’s stock.

Repligen Price Performance

Shares of RGEN stock opened at $164.89 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24. The stock’s fifty day simple moving average is $178.64 and its 200 day simple moving average is $174.49. Repligen Co. has a one year low of $110.45 and a one year high of $211.13. The firm has a market cap of $9.21 billion, a price-to-earnings ratio of 659.56, a P/E/G ratio of 5.58 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The firm had revenue of $151.31 million during the quarter, compared to the consensus estimate of $150.06 million. During the same period in the previous year, the company posted $0.64 EPS. The firm’s revenue for the quarter was down 17.1% compared to the same quarter last year. On average, analysts expect that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.